Cure My Disease

Don't miss your cure!

 Log in / Sign up

New blood test could spot spread of rare eye cancer

NCT ID NCT01334008

Knowledge-focused Sponsor: Institut Curie Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aimed to develop a blood test that can detect tiny bits of tumor DNA in patients with metastatic choroidal melanoma, a rare eye cancer that has spread. Researchers tested blood samples from 40 adults to see if the test could reliably find cancer DNA. The goal was to create a simpler way to monitor the disease without needing repeated tissue biopsies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

40 people

The number who actually took part.

Start date

Apr 2011

Finished

May 2012

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age \> or = 18 years. * Patient with a metastatic choroidal melanoma. * Patient with tumor or metastasis available for GNAQ (Guanine nucleotide blinding protein) status characterization. * Patient able to stand a blood collection. * Signed written informed consent approved by competent authority and ethic committee. Exclusion Criteria: * Patient without social protection/insurance. * Current pregnancy and lactation. * All social, medical, psychological, situations making the study impossible. * Person deprived of liberty.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Choroidal melanoma, diffuse are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant choroid melanoma Uveal Melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Choroidal melanoma, diffuse

Contacts and locations

Locations

  • Institut Curie

    Paris, 75005, France